These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1919169)

  • 1. Effects of tumor-necrosis-factor-activated neutrophils on tumor cell survival.
    Shau H
    Immunol Res; 1991; 10(2):114-21. PubMed ID: 1919169
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities.
    Grunfeld C; Palladino MA
    Adv Intern Med; 1990; 35():45-71. PubMed ID: 2405602
    [No Abstract]   [Full Text] [Related]  

  • 4. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Tsiatas ML; Gritzapis AD; Papamichail M
    Eur J Immunol; 2000 Jul; 30(7):1957-66. PubMed ID: 10940885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin inhibits tumor cell cytotoxicity mediated through natural killer cells, lymphokine-activated killer cells, monocytes, and tumor necrosis factor.
    LaPushin R; Totpal K; Higuchi M; Aggarwal BB
    J Clin Immunol; 1994 Jan; 14(1):39-49. PubMed ID: 8132736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection with the tumor necrosis factor-alpha gene.
    Tashiro T; Yoshida J; Mizuno M; Sugita K
    J Neurosurg; 1993 Feb; 78(2):252-6. PubMed ID: 8421207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
    Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
    Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of NK cells through the 80-kDa TNFR (CD120b).
    Mason AT; McVicar DW; Smith CA; Young HA; Ware CF; Ortaldo JR
    J Leukoc Biol; 1995 Aug; 58(2):249-55. PubMed ID: 7543923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms.
    Bean P; Mazumder A
    Immunobiology; 1992 Jun; 185(1):63-77. PubMed ID: 1398742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.
    Koberda J; Bergmann L; Mitrou PS; Hoelzer D
    J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of pretreating target cells with iron citrate on cytolysis, mediated by tumor necrosis factor and lymphokine-activated killer cells].
    Kalinina AR; Sadovnikov VB; Vodianik MA; Pashkevich AP
    Dokl Akad Nauk; 1994 Jan; 334(2):237-40. PubMed ID: 8167581
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target cell membrane modification and susceptibility to lymphokine activated killer cell mediated lysis. I. Trinitrophenyl has no effect on murine normal cells and tumors.
    Lefor AT
    J Surg Res; 1991 Oct; 51(4):316-23. PubMed ID: 1921371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.
    Eckert K; Grünberg E; Immenschuh P; Garbin F; Kreuser ED; Maurer HR
    J Cancer Res Clin Oncol; 1997; 123(8):420-8. PubMed ID: 9292704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of lymphokine-activated killer induction by neutrophils.
    Shau HY; Kim A
    J Immunol; 1988 Dec; 141(12):4395-402. PubMed ID: 3264311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoregulatory effects of the herba Epimediia glycoside icariin.
    He W; Sun H; Yang B; Zhang D; Kabelitz D
    Arzneimittelforschung; 1995 Aug; 45(8):910-3. PubMed ID: 7575760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of lymphokine-activated killer (LAK) cells.
    Ortaldo JR
    Prog Clin Biol Res; 1987; 244():197-206. PubMed ID: 2443928
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of lymphokine-activated killer- and natural killer-mediated cytotoxicities by neutrophils.
    Shau HY; Golub SH
    J Immunol; 1989 Aug; 143(3):1066-72. PubMed ID: 2787346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of the neutrophils in the pathogenesis of malignant growth].
    Kashulina AP; Tereshchenko IP
    Eksp Onkol; 1985; 7(6):3-9. PubMed ID: 3910404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
    Yang SC; Fry KD; Grimm EA; Roth JA
    Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.